Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Nanomaterial-based drug delivery systems (NBDDS) are widely used to improve the safety
and therapeutic efficacy of encapsulated drugs due to their unique physicochemical and …

Microcatheters have enabled diverse minimally invasive endovascular operations and
notable health benefits compared with open surgeries. However, with tortuous routes far …

Utilizing neutrophils (NEs) to target and deliver nanodrugs to inflammation sites has
received considerable attention. NEs are involved in the formation and development of …

After the protocol-related indecisive clinical trial of Oxygent, a perfluorooctylbromide/
phospholipid nanoemulsion, in cardiac surgery, that often unduly assigned the observed …

Mesoporous silica nanocarrier (MSN) preparations have a wide range of medical
applications. Studying the biocompatibility of MSN is an important part of clinical …

Microbubbles (MBs) were observed for the first time in vivo as a curious consequence of
quick saline injection during ultrasound (US) imaging of the aortic root, more than 50 years …

Fast and effective thrombolysis using tissue plasminogen activator (tPA) is limited by the
poor delivery efficiency of thrombolytic drugs, which is induced by an interrupted …

Currently, the limited efficacy of antithrombotic treatments is attributed to the inadequacy of
pure drugs and the low ability of drugs to target the thrombus site. More importantly, timely …

Thrombosis is a leading global cause of death, in part due to the low efficacy of thrombolytic
therapy. Here, we describe a method for precise delivery and accurate dosing of tissue …